Novo Nordisk is making a significant investment in a new manufacturing facility located in Clayton, North Carolina. The company announced a $4.1 billion plan to construct this plant, aiming to increase the production of popular drugs like Wegovy and Ozempic. The demand for these medications has been high, leading to occasional shortages in the U.S. Novo Nordisk is committed to expanding its manufacturing capacity, with a total investment of $6.8 billion planned for this year.
The new facility will focus on filling and packaging syringes and injection pens for these essential drugs. Doug Langa, Novo Nordisk’s North American operations head, expressed excitement about the investment, emphasizing the company’s dedication to serving more patients. This strategic move will not only address supply challenges but also support the company’s growth and innovation in the pharmaceutical industry.
Source from www.cnbc.com